Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HP Inc (HPQ) vs Heron Therapeutics Inc (HRTX) Price & Performance

Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

HP Inc vs Heron Therapeutics Inc — how do they compare? HP Inc trades at $28.76 (market cap $26.59B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: HP Inc is far larger — about 432.6× Heron Therapeutics Inc's market cap, and HP Inc pays a 4.13% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HPQHRTX
Market Cap
$26.59B$61.47M
Sector
TechnologyHealth
52-Week High
$30.05$1.49
52-Week Low
$18.20$0.32
Enterprise Value
$33.75B$168.21M
Dividend Yield
4.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HP Inc

HPQ trades at $28.72, down 3.62% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $55.3B in 2025, though net margins compressed to 4.45%. The stock offers a dividend yield near 4% and trades at attractive valuations with a P/E of 10.77 and P/S of 0.48. Recent news highlights AI-driven cost savings and a potential 2027 upgrade cycle, while institutional activity shows mixed positioning adjustments.

Outlook: HPQ presents value with low multiples and dividend income, but faces PC market volatility and margin pressure. Risks include competitive threats and debt levels, while catalysts include AI product adoption. Analyst consensus is mixed with a hold rating, but technical strength and earnings consistency support cautious optimism for patient investors.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About HP Inc

HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.

Read more on HPQ

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX